F. J. Accurso, R. B. Moss, R. W. Wilmott, R. D. Anbar, A. E. Schaberg et al., Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function, Am. J. Respir. Crit. Care Med, vol.183, pp.627-634, 2011.

D. Adam, J. Roux-delrieu, E. Luczka, A. Bonnomet, J. Lesage et al., Cystic fibrosis airway epithelium remodelling: involvement of inflammation, J. Pathol, vol.235, pp.408-419, 2015.

J. Agier, M. Efenberger, and E. Brzezin?ka-b?aszczyk, Review paper Cathelicidin impact on inflammatory cells. Cent, Eur. J. Immunol, vol.2, pp.225-235, 2015.

E. W. Alton, D. K. Armstrong, D. Ashby, K. J. Bayfield, D. Bilton et al., Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebocontrolled, phase 2b trial, Lancet Respirat. Med, vol.3, issue.15, pp.245-248, 2015.

E. W. Alton, J. M. Beekman, A. C. Boyd, J. Brand, M. S. Carlon et al., Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis, Thorax, 2017.

A. Arampatzioglou, D. Papazoglou, T. Konstantinidis, A. Chrysanthopoulou, A. Mitsios et al., Clarithromycin Enhances the Antibacterial Activity and Wound Healing Capacity in Type 2 Diabetes Mellitus by Increasing LL-37 Load on, Neutrophil Extracellular Traps. Front. Immunol, vol.9, p.2064, 2018.

D. S. Armstrong, K. Grimwood, R. Carzino, J. B. Carlin, A. Olinsky et al., Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis, BMJ, vol.310, pp.1571-1572, 1995.

K. R. Atanasova and L. R. Reznikov, Strategies for measuring airway mucus and mucins, Respir. Res, vol.20, p.261, 2019.

H. S. Auerbach, M. Williams, J. A. Kirkpatrick, and H. R. Colten, Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis, Lancet, vol.2, pp.686-688, 1985.

M. Aureli, D. Schiumarini, N. Loberto, R. Bassi, A. Tamanini et al., Unravelling the role of sphingolipids in cystic fibrosis lung disease, Chem. Phys. Lipids, vol.200, pp.94-103, 2016.

A. Balazs and M. A. Mall, Mucus obstruction and inflammation in early cystic fibrosis lung disease: Emerging role of the IL-1 signaling pathway, Pediatr. Pulmonol, vol.54, pp.5-12, 2019.

I. M. Balfour-lynn, W. , and K. , Inhaled corticosteroids for cystic fibrosis, Cochrane Database Syst. Rev, vol.10, p.1915, 2014.

I. M. Balfour-lynn, B. Lees, P. Hall, G. Phillips, M. Khan et al., Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis, Am. J. Respir. Crit. Care Med, vol.173, pp.1356-1362, 2006.

R. Bals, D. J. Weiner, R. L. Meegalla, F. Accurso, and J. M. Wilson, Salt-Independent Abnormality of Antimicrobial Activity in Cystic Fibrosis Airway Surface Fluid, Am. J. Respir. Cell Mol. Biol, vol.25, pp.21-25, 2001.

B. J. Banaschewski, B. Baer, C. Arsenault, T. Jazey, E. J. Veldhuizen et al., The Antibacterial and Anti-inflammatory Activity of Chicken Cathelicidin-2 combined with Exogenous Surfactant for the Treatment of Cystic Fibrosis-Associated Pathogens, Sci. Rep, vol.7, p.15545, 2017.

P. Bardin, E. Marchal-duval, F. Sonneville, S. Blouquit-laye, N. Rousselet et al., Small RNA and transcriptome sequencing reveal the role of miR-199a-3p in inflammatory processes in cystic fibrosis airways, J. Pathol, vol.245, pp.410-420, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-02390385

P. Bardin, F. Sonneville, H. Corvol, and O. Tabary, Emerging microRNA Therapeutic Approaches for Cystic Fibrosis, Front. Pharmacol, vol.9, p.1113, 2018.

P. Bardin, T. Foussignière, N. Rousselet, C. Rebeyrol, J. C. Porter et al., miR-636: A Newly-Identified Actor for the Regulation of Pulmonary Inflammation in Cystic Fibrosis, Front. Immunol, vol.10, p.2643, 2019.
URL : https://hal.archives-ouvertes.fr/inserm-02390394

P. J. Barnes, Transcription factors in airway diseases, Lab. Invest, vol.86, pp.867-872, 2006.

M. V. Bautista, Y. Chen, V. S. Ivanova, M. K. Rahimi, A. M. Watson et al., IL-8 Regulates Mucin Gene Expression at the Posttranscriptional Level in Lung Epithelial Cells, J. Immunol, vol.183, pp.2159-2166, 2009.

Y. Belkaid and T. W. Hand, Role of the Microbiota in Immunity and Inflammation, Cell, vol.157, pp.121-141, 2014.

R. Benedetto, J. Ousingsawat, P. Wanitchakool, Y. Zhang, M. J. Holtzman et al., Epithelial Chloride Transport by CFTR Requires TMEM16A, Sci. Rep, vol.7, p.12397, 2017.

R. Benedetto, J. Ousingsawat, I. Cabrita, M. Pinto, J. R. Lerias et al., Plasma membrane-localized TMEM16 proteins are indispensable for expression of CFTR, J. Mol. Med. (Berl.), vol.97, pp.711-722, 2019.

F. Blasi, C. Page, G. M. Rossolini, L. Pallecchi, M. G. Matera et al., The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections, Respir. Med, vol.117, pp.190-197, 2016.

M. Brook, G. H. Tomlinson, K. Miles, R. W. Smith, A. G. Rossi et al., Neutrophil-derived alpha defensins control inflammation by inhibiting macrophage mRNA translation, Proc. Natl. Acad. Sci, vol.113, pp.4350-4355, 2016.

S. H. Burstein, Ajulemic acid: potential treatment for chronic inflammation, Pharmacol. Res. Perspect, vol.6, p.394, 2018.

B. Button, L. H. Cai, C. Ehre, M. Kesimer, D. B. Hill et al., A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia, Science, vol.337, pp.937-941, 2012.

W. Bystrzycka, A. Manda-handzlik, S. Sieczkowska, A. Moskalik, U. Demkow et al., Azithromycin and Chloramphenicol Diminish Neutrophil Extracellular Traps (NETs) Release, Int. J. Mol. Sci, vol.18, p.2666, 2017.

I. Callebaut, B. Hoffmann, P. Lehn, and J. P. Mornon, Molecular modelling and molecular dynamics of CFTR, Cell Mol. Life Sci, vol.74, pp.3-22, 2017.

A. M. Cantin, G. Bilodeau, C. Ouellet, J. Liao, and J. W. Hanrahan, Oxidant stress suppresses CFTR expression, Am. J. Physiol. Cell Physiol, vol.290, 2006.

A. M. Cantin, T. B. White, C. E. Cross, H. J. Forman, R. J. Sokol et al., Antioxidants in cystic fibrosis, Conclusions from the CF antioxidant workshop, vol.4, pp.15-31, 2003.

A. M. Cantin, D. Hartl, M. W. Konstan, and J. F. Chmiel, Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy, J. Cyst. Fibros, vol.14, pp.419-430, 2015.

A. Caputo, E. Caci, L. Ferrera, N. Pedemonte, C. Barsanti et al., TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity, Science, vol.322, pp.590-594, 2008.

A. Caretti, A. Bragonzi, M. Facchini, I. De-fino, C. Riva et al., , 2014.

, Anti-inflammatory action of lipid nanocarrier-delivered myriocin: therapeutic potential in cystic fibrosis, Biochim. Biophys. Acta, vol.1840, pp.586-594

A. J. Causer, J. K. Shute, M. H. Cummings, A. I. Shepherd, M. Gruet et al., Circulating biomarkers of antioxidant status and oxidative stress in people with cystic fibrosis: A systematic review and meta-analysis, Redox Biol, vol.32, p.101436, 2020.
URL : https://hal.archives-ouvertes.fr/hal-02471393

J. D. Chalmers, K. L. Moffitt, G. Suarez-cuartin, O. Sibila, S. Finch et al., Neutrophil Elastase Activity Is Associated with Exacerbations and Lung Function Decline in Bronchiectasis, Am. J. Respir. Crit. Care Med, vol.195, pp.1384-1393, 2017.

J. Chastre, R. Wunderink, P. Prokocimer, M. Lee, K. Kaniga et al., Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study, Crit. Care Med, vol.36, pp.1089-1096, 2008.

M. E. Chirgwin, M. R. Dedloff, A. M. Holban, and M. C. Gestal, Novel Therapeutic Strategies Applied to Pseudomonas aeruginosa Infections in Cystic Fibrosis, Materials, vol.12, p.4093, 2019.

K. G. Choi, S. Napper, and N. Mookherjee, Human cathelicidin LL-37 and its derivative IG-19 regulate interleukin-32-induced inflammation, Immunology, vol.143, pp.68-80, 2014.

P. E. Christie, B. W. Spur, and T. H. Lee, The effects of lipoxin A4 on airway responses in asthmatic subjects, Am. Rev. Respir. Dis, vol.145, pp.1281-1284, 1992.

C. Cigana, F. Bernardini, M. Facchini, B. Alcala-franco, C. Riva et al., Efficacy of the Novel Antibiotic POL7001 in Preclinical Models of Pseudomonas aeruginosa Pneumonia, Antimicrob. Agents Chemother, vol.60, pp.4991-5000, 2016.

O. Ciofu, S. Smith, and J. Lykkesfeldt, Antioxidant supplementation for lung disease in cystic fibrosis, Cochrane Database Syst. Rev, vol.10, p.7020, 2019.

A. Clement, A. Tamalet, E. Leroux, S. Ravilly, B. Fauroux et al., Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial, Thorax, vol.61, pp.895-902, 2006.

T. S. Cohen and A. Prince, Cystic fibrosis: a mucosal immunodeficiency syndrome, Nat. Med, vol.18, pp.509-519, 2012.

H. Corvol, C. Fitting, K. Chadelat, J. Jacquot, O. Tabary et al., Distinct cytokine production by lung and blood neutrophils from children with cystic fibrosis, Am. J. Physiol. Lung Cell Mol. Physiol, vol.284, pp.997-1003, 2003.

J. R. Crosby, C. Zhao, C. Jiang, D. Bai, M. Katz et al., Inhaled ENaC antisense oligonucleotide ameliorates cystic fibrosis-like lung disease in mice, J. Cyst. Fibros, vol.16, pp.671-680, 2017.

H. L. Danahay, S. Lilley, R. Fox, H. Charlton, J. Sabater et al., TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis, Am. J. Respir. Crit. Care Med, vol.201, issue.8, pp.946-954, 2020.

J. C. Davies, S. M. Moskowitz, C. Brown, A. Horsley, M. A. Mall et al., VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles, N. Engl. J. Med, vol.379, pp.1599-1611, 2018.

M. De-fenza, D. D'alonzo, A. Esposito, S. Munari, N. Loberto et al., Exploring the effect of chirality on the therapeutic potential of Nalkyl-deoxyiminosugars: anti-inflammatory response to Pseudomonas aeruginosa infections for application in CF lung disease, Eur. J. Med. Chem, vol.175, pp.63-71, 2019.

D. Santi, C. Fernandez-fernandez, E. Gaul, R. Vencken, S. Glasgow et al., Precise Targeting of miRNA Sites Restores CFTR Activity in CF Bronchial Epithelial Cells, Mol. Ther, vol.28, issue.4, pp.1190-1199, 2020.

C. Delacourt, L. Bourgeois, M. D'ortho, M. P. Doit, C. Scheinmann et al., Imbalance between 95 kDa type IV collagenase and tissue inhibitor of metalloproteinases in sputum of patients with cystic fibrosis, Am. J. Respir. Crit. Care Med, vol.152, pp.765-774, 1995.

F. Dif, Y. Z. Wu, P. R. Burgel, M. Ollero, D. Leduc et al., Critical role of cytosolic phospholipase A2{alpha} in bronchial mucus hypersecretion in CFTR-deficient mice, Eur. Respir. J, vol.36, 2010.

S. H. Donaldson, G. M. Solomon, P. L. Zeitlin, P. A. Flume, A. Casey et al., Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR, J. Cystic Fibrosis, vol.16, pp.371-379, 2017.

G. Doring, Prevention of Pseudomonas aeruginosa infection in cystic fibrosis patients, Int. J. Med. Microbiol, vol.300, pp.573-577, 2010.

Y. C. Duijvestijn and P. L. Brand, Systematic review of N-acetylcysteine in cystic fibrosis, Acta Paediatr, vol.88, pp.38-41, 1999.

C. Ehre, C. Ridley, and D. J. Thornton, Cystic fibrosis: an inherited disease affecting mucin-producing organs, Int. J. Biochem. Cell Biol, vol.52, pp.136-145, 2014.

C. Ehre, Z. L. Rushton, B. Wang, L. N. Hothem, C. B. Morrison et al., An Improved Inhaled Mucolytic to Treat Airway Mucoobstructive Diseases, Am. J. Respir. Crit. Care Med, vol.199, pp.171-180, 2019.

J. S. Elborn, A. Horsley, G. Macgregor, D. Bilton, R. Grosswald et al., Phase I Studies of Acebilustat: Biomarker Response and Safety in Patients with Cystic Fibrosis, Clin. Transl. Sci, vol.10, pp.28-34, 2017.

J. S. Elborn, S. Ahuja, E. Springman, J. Mershon, R. Grosswald et al., EMPIRE-CF: A phase II randomized placebo-controlled trial of oncedaily, oral acebilustat in adult patients with cystic fibrosis -Study design and patient demographics, Contemp. Clin. Trials, vol.72, pp.86-94, 2018.

J. S. Elborn, Cystic fibrosis, Lancet, vol.388, issue.16, pp.576-582, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02299268

Q. J. Epps, K. L. Epps, D. C. Young, and J. T. Zobell, State of the art in cystic fibrosis pharmacology-Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: I. Anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotics, Pediatr. Pulmonol, vol.55, issue.1, pp.35-57, 2019.

A. Equi, I. M. Balfour-lynn, A. Bush, and M. Rosenthal, Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial, Lancet, vol.360, pp.978-984, 2002.

A. Ermund, C. V. Recktenwald, G. Skjåk-braek, L. N. Meiss, E. Onsøyen et al., OligoG CF-5/20 normalizes cystic fibrosis mucus by chelating calcium, Clin. Exp. Pharmacol. Physiol, vol.44, pp.639-647, 2017.

C. R. Esther, M. S. Muhlebach, C. Ehre, D. B. Hill, M. C. Wolfgang et al., Mucus accumulation in the lungs precedes structural changes and infection in children with cystic fibrosis, Sci. Transl. Med, vol.11, 2019.

E. Fabbri, M. Borgatti, G. Montagner, N. Bianchi, A. Finotti et al., Expression of miR-93 and IL-8 During Pseudomonas aeruginosa Mediated Induction of Pro-Inflammatory Responses, Am. J. Respir. Cell Mol. Biol, vol.50, issue.6, pp.1144-1155, 2014.

J. V. Fahy and B. F. Dickey, Airway mucus function and dysfunction, N. Engl. J. Med, vol.363, pp.2233-2247, 2010.

B. B. Finlay and R. E. Hancock, Can innate immunity be enhanced to treat microbial infections?, Nat. Rev. Microbiol, vol.2, pp.497-504, 2004.

S. D. Freedman, P. G. Blanco, M. M. Zaman, J. C. Shea, M. Ollero et al., Association of cystic fibrosis with abnormalities in fatty acid metabolism, N. Engl. J. Med, vol.350, pp.560-569, 2004.

P. Fu, D. L. Ebenezer, A. W. Ha, V. Suryadevara, A. Harijith et al., Nuclear lipid mediators: Role of nuclear sphingolipids and sphingosine-1-phosphate signaling in epigenetic regulation of inflammation and gene expression, J. Cell. Biochem, vol.119, issue.8, pp.6337-6353, 2018.

A. Gaggar, A. Hector, P. E. Bratcher, M. A. Mall, M. Griese et al., The role of matrix metalloproteinases in cystic fibrosis lung disease, Eur. Respir. J, vol.38, pp.721-727, 2011.

A. Gaggar, J. Chen, J. F. Chmiel, H. L. Dorkin, P. A. Flume et al., Inhaled alpha1-proteinase inhibitor therapy in patients with cystic fibrosis, J. Cyst. Fibros, vol.15, pp.227-233, 2016.

F. Galli, A. Battistoni, R. Gambari, A. Pompella, A. Bragonzi et al., Fibrosis, Oxidative stress and antioxidant therapy in cystic fibrosis, Biochim. Biophys. Acta, vol.1822, pp.690-713, 2012.

I. Garcia-verdugo, F. Benmohamed, S. Tattermusch, D. Leduc, G. Charpigny et al., A role for 12R-lipoxygenase in MUC5AC expression by respiratory epithelial cells, Eur. Respirat. J, vol.40, pp.714-723, 2012.
URL : https://hal.archives-ouvertes.fr/hal-01004450

R. Geitani, C. Ayoub-moubareck, L. Touqui, K. Sarkis, and D. , Cationic antimicrobial peptides: alternatives and/or adjuvants to antibiotics active against methicillin-resistant Staphylococcus aureus and multidrugresistant Pseudomonas aeruginosa, BMC Microbiol, vol.19, p.54, 2019.

B. P. Giroir, P. J. Scannon, L. , and M. , Bactericidal/permeabilityincreasing protein-lessons learned from the phase III, randomized, clinical trial of rBPI21 for adjunctive treatment of children with severe meningococcemia, Crit. Care Med, vol.29, pp.130-135, 2001.

A. M. Glasgow, C. De-santi, and C. M. Greene, Non-coding RNA in cystic fibrosis, Biochem. Soc. Trans, vol.46, issue.3, pp.619-630, 2018.

S. M. Gregory, S. A. Nazir, and J. P. Metcalf, Implications of the innate immune response to adenovirus and adenoviral vectors, Future Virol, vol.6, pp.357-374, 2011.

C. Guilbault, J. B. De-sanctis, G. Wojewodka, Z. Saeed, C. Lachance et al., Fenretinide corrects newly found ceramide deficiency in cystic fibrosis, Am. J. Respir. Cell Mol. Biol, vol.38, pp.47-56, 2008.

C. Guilbault, G. Wojewodka, Z. Saeed, M. Hajduch, E. Matouk et al., Cystic fibrosis fatty acid imbalance is linked to ceramide deficiency and corrected by fenretinide, Am. J. Respir. Cell Mol. Biol, vol.41, pp.100-106, 2009.

K. Guntupalli, N. Dean, P. E. Morris, V. Bandi, B. Margolis et al., A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis, Crit. Care Med, vol.41, pp.706-716, 2013.

G. M. Halford, M. Lordkipanidze, and S. P. Watson, 50th anniversary of the discovery of ibuprofen: an interview with Dr Stewart Adams, Platelets, vol.23, pp.415-422, 2012.

R. E. Hancock, E. F. Haney, and E. E. Gill, The immunology of host defence peptides: beyond antimicrobial activity, Nat. Rev. Immunol, vol.16, pp.321-334, 2016.

D. Haydar, T. J. Cory, S. E. Birket, B. S. Murphy, K. R. Pennypacker et al., Azithromycin Polarizes Macrophages to an M2 Phenotype via Inhibition of the STAT1 and NF-kB Signaling Pathways, J. Immunol, vol.203, 2019.

A. G. Henderson, C. Ehre, B. Button, L. H. Abdullah, L. H. Cai et al., Cystic fibrosis airway secretions exhibit mucin hyperconcentration and increased osmotic pressure, J. Clin. Invest, vol.124, pp.3047-3060, 2014.

M. O. Henke and F. Ratjen, Mucolytics in cystic fibrosis, Paediatric Respirat. Rev, vol.8, pp.24-29, 2007.

G. Higgins, F. Ringholz, P. Buchanan, P. Mcnally, and V. Urbach, Physiological impact of abnormal lipoxin A(4) production on cystic fibrosis airway epithelium and therapeutic potential, BioMed. Res. Int, p.781087, 2015.

H. Horati, H. M. Janssens, C. Margaroli, M. Veltman, M. Stolarczyk et al., Airway profile of bioactive lipids predicts early progression of lung disease in cystic fibrosis, J. Cystic Fibrosis, vol.46, issue.3, pp.619-630, 2020.

M. Hou, R. Sun, M. Hupe, P. L. Kim, K. Park et al., Topical apigenin improves epidermal permeability barrier homoeostasis in normal murine skin by divergent mechanisms, Exp. Dermatol, vol.22, pp.210-215, 2013.

C. Hubeau, M. Lorenzato, J. P. Couetil, D. Hubert, D. Dusser et al., Quantitative analysis of inflammatory cells infiltrating the cystic fibrosis airway mucosa, Clin. Exp. Immunol, vol.124, pp.69-76, 2001.
URL : https://hal.archives-ouvertes.fr/inserm-00152211

A. M. Hunt, A. M. Glasgow, H. Humphreys, and C. M. Greene, Alpha-1 Antitrypsin-A Target for MicroRNA-Based Therapeutic Development for Cystic Fibrosis, Int. J. Mol. Sci, vol.21, p.836, 2020.

J. E. Ideozu, X. Zhang, S. Mccolley, and H. Levy, Transcriptome Profiling and Molecular Therapeutic Advances in Cystic Fibrosis: Recent Insights, Genes (Basel), vol.10, p.180, 2019.

J. Jacquot, O. Tabary, P. Le-rouzic, C. , and A. , Airway epithelial cell inflammatory signalling in cystic fibrosis, Int. J. Biochem. Cell Biol, vol.40, pp.1703-1715, 2008.

J. Jacquot, O. Tabary, C. , and A. , Hyperinflammation in airways of cystic fibrosis patients: what's new?, Expert Rev. Mol. Diagn, vol.8, pp.359-363, 2008.

H. H. Jarosz-griffiths, T. Scambler, C. H. Wong, S. Lara-reyna, J. Holbrook et al., Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis, Elife, vol.9, 2020.

J. Jung, J. H. Nam, H. W. Park, U. Oh, J. H. Yoon et al., Dynamic modulation of ANO1/TMEM16A HCO3(-) permeability by Ca2+/calmodulin, Proc. Natl. Acad. Sci. U.S.A, vol.110, pp.360-365, 2013.

C. L. Karp, L. M. Flick, K. W. Park, S. Softic, T. M. Greer et al., Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway, Nat. Immunol, vol.5, pp.388-392, 2004.

D. Keating, G. Marigowda, L. Burr, C. Daines, M. A. Mall et al., VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles, N. Engl. J. Med, vol.379, pp.1612-1620, 2018.

T. Z. Khan, J. S. Wagener, T. Bost, J. Martinez, F. J. Accurso et al., Early pulmonary inflammation in infants with cystic fibrosis, Am. J. Respir. Crit. Care Med, vol.151, pp.1075-1082, 1995.

M. A. Khan, Z. S. Ali, N. Sweezey, H. Grasemann, and N. Palaniyar, Progression of Cystic Fibrosis Lung Disease from Childhood to Adulthood: Neutrophils, Neutrophil Extracellular Trap (NET) Formation, and NET Degradation, Genes, vol.10, p.183, 2019.

B. J. Kim, Y. K. Rho, H. I. Lee, M. S. Jeong, K. Li et al., The effect of calcipotriol on the expression of human beta defensin-2 and LL-37 in cultured human keratinocytes, Clin. Dev. Immunol, p.645898, 2009.

M. R. Knowles, L. L. Clarke, and R. C. Boucher, Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis, N. Engl. J. Med, vol.325, pp.533-538, 1991.

M. W. Konstan, J. E. Krenicky, M. R. Finney, H. L. Kirchner, K. A. Hilliard et al., Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects, J. Pharmacol. Exp. Ther, vol.306, pp.1086-1091, 2003.

T. Konstantinidis, K. Kambas, A. Mitsios, M. Panopoulou, V. Tsironidou et al., Immunomodulatory Role of Clarithromycin in Acinetobacter baumannii Infection via Formation of Neutrophil Extracellular Traps, Antimicrobial. Agents Chemother, vol.60, pp.1040-1048, 2016.

S. Kudoh, T. Uetake, K. Hagiwara, M. Hirayama, L. H. Hus et al., Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis, Nihon Kyobu Shikkan Gakkai zasshi, vol.25, pp.632-642, 1987.

R. G. Kurumbail, A. M. Stevens, J. K. Gierse, J. J. Mcdonald, R. A. Stegeman et al., Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents, Nature, vol.384, pp.644-648, 1996.

Y. Lai and R. L. Gallo, AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense, Trends Immunol, vol.30, pp.131-141, 2009.

I. Lampronti, M. C. Dechecchi, A. Rimessi, V. Bezzerri, E. Nicolis et al., beta-Sitosterol Reduces the Expression of Chemotactic Cytokine Genes in Cystic Fibrosis Bronchial Epithelial Cells, Front. Pharmacol, vol.8, p.236, 2017.

L. C. Lands and S. Stanojevic, Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis, Cochrane Database Syst. Rev, vol.4, p.1505, 2007.

L. C. Lands and S. Stanojevic, Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis, Cochrane Database Syst. Rev, vol.4, p.1505, 2016.

L. C. Lands and S. Stanojevic, Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis, Cochrane Database Syst. Rev, 2019.

O. Laselva, T. A. Stone, C. E. Bear, and C. M. Deber, Anti-Infectives Restore ORKAMBI((R)) Rescue of F508del-CFTR Function in Human Bronchial Epithelial Cells Infected with Clinical Strains of P. aeruginosa, Biomolecules, vol.10, p.334, 2020.

N. Law, C. Logan, G. Yung, C. L. Furr, S. M. Lehman et al., Successful adjunctive use of bacteriophage therapy for treatment of multidrugresistant Pseudomonas aeruginosa infection in a cystic fibrosis patient, Infection, vol.47, pp.665-668, 2019.

A. L. Lazaar, L. E. Sweeney, A. J. Macdonald, N. E. Alexis, C. Chen et al., SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans, Br. J. Clin. Pharmacol, vol.72, pp.282-293, 2011.

F. Lecaille, G. Lalmanach, and P. M. Andrault, Antimicrobial proteins and peptides in human lung diseases: A friend and foe partnership with host proteases, Biochimie, vol.122, pp.151-168, 2016.

M. Lopes-pacheco, CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine, Front. Pharmacol, vol.10, p.1662, 2019.

K. Loth, A. Vergnes, C. Barreto, S. N. Voisin, H. Meudal et al., The Ancestral N-Terminal Domain of Big Defensins Drives Bacterially Triggered Assembly into Antimicrobial Nanonets, vol.10, pp.1821-1840, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02328576

B. Lubamba, J. Lebacq, G. Reychler, E. Marbaix, P. Wallemacq et al., Inhaled phosphodiesterase type 5 inhibitors restore chloride transport in cystic fibrosis mice, Eur. Respir. J, vol.37, pp.72-78, 2011.

T. Magrone, M. A. Russo, J. , and E. , Antimicrobial Peptides in Human Disease: Therapeutic Approaches. Second of Two Parts, Curr. Pharm. Des, vol.24, pp.1148-1156, 2018.

R. G. Masera, A. Bateman, M. Muscettola, S. Solomon, and A. Angeli, , 1996.

, Corticostatins/defensins inhibit in vitro NK activity and cytokine production by human peripheral blood mononuclear cells, Regul. Pept, vol.62, pp.13-21

M. Mayer, Lumacaftor-ivacaftor (Orkambi) for cystic fibrosis: behind the 'breakthrough', Evid. Based. Med, vol.21, pp.83-86, 2016.

N. G. Mcelvaney, B. Doujaiji, M. J. Moan, M. R. Burnham, M. C. Wu et al., Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis, Am. Rev. Respir. Dis, vol.148, pp.1056-1060, 1993.

O. J. Mcelvaney, Z. Zaslona, K. Becker-flegler, E. M. Palsson-mcdermott, F. Boland et al., Specific Inhibition of the NLRP3 Inflammasome as an Antiinflammatory Strategy in Cystic Fibrosis, Am. J. Respir. Crit. Care Med, vol.200, pp.1381-1391, 2019.

J. E. Mcinturff, S. J. Wang, T. Machleidt, T. R. Lin, A. Oren et al., Granulysin-derived peptides demonstrate antimicrobial and antiinflammatory effects against Propionibacterium acnes, J. Invest. Dermatol, vol.125, pp.256-263, 2005.

M. C. Mckelvey, S. Weldon, D. F. Mcauley, M. A. Mall, and C. C. Taggart, Targeting Proteases in Cystic Fibrosis Lung Disease. Paradigms, Progress, and Potential, Am. J. Respir. Crit. Care Med, vol.201, pp.141-147, 2020.

S. Medjane, B. Raymond, Y. Wu, and L. Touqui, Impact of CFTR DeltaF508 mutation on prostaglandin E2 production and type IIA phospholipase A2 expression by pulmonary epithelial cells, Am. J. Physiol. Lung Cell Mol. Physiol, vol.289, pp.816-824, 2005.

P. G. Middleton, M. A. Mall, P. Dr?v??ek, L. C. Lands, E. F. Mckone et al., Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele, New Engl. J. Med, vol.381, pp.1809-1819, 2019.

A. Mingione, M. Dei-cas, F. Bonezzi, A. Caretti, M. Piccoli et al., Inhibition of Sphingolipid Synthesis as a Phenotype-Modifying Therapy in Cystic Fibrosis, Cell Physiol. Biochem, vol.54, pp.110-125, 2020.

F. B. Mohamed, I. Garcia-verdugo, M. Medina, V. Balloy, M. Chignard et al., A Crucial Role of Flagellin in the Induction of Airway Mucus Production by Pseudomonas aeruginosa, PloS One, vol.7, 2012.

M. Moller-kristensen, W. K. Ip, L. Shi, L. D. Gowda, M. R. Hamblin et al., Deficiency of Mannose-Binding Lectin Greatly Increases Susceptibility to Postburn Infection with Pseudomonas aeruginosa, J. Immunol, vol.176, pp.1769-1775, 2006.

N. Mookherjee, P. Hamill, J. Gardy, D. Blimkie, R. Falsafi et al., Systems biology evaluation of immune responses induced by human host defence peptide LL-37 in mononuclear cells, Mol. Biosyst, vol.5, pp.483-496, 2009.

E. Morello, E. Saussereau, D. Maura, M. Huerre, L. Touqui et al., Pulmonary Bacteriophage Therapy on Pseudomonas aeruginosa Cystic Fibrosis Strains: First Steps Towards Treatment and Prevention, PloS One, vol.6, 2011.
URL : https://hal.archives-ouvertes.fr/pasteur-01425539

G. Morrison, F. Kilanowski, D. Davidson, and J. Dorin, Characterization of the Mouse Beta Defensin 1, Defb1. Mutant Mouse Model, Infection Immun, vol.70, pp.3053-3060, 2002.

R. B. Moss, S. J. Mistry, M. W. Konstan, J. M. Pilewski, E. Kerem et al., Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis, J. Cyst. Fibros, vol.12, pp.241-248, 2013.

R. B. Moss, Pitfalls of drug development: lessons learned from trials of denufosol in cystic fibrosis, J. Pediatr, vol.162, pp.676-680, 2013.

C. Mueller, Q. Tang, A. Gruntman, K. Blomenkamp, J. Teckman et al., Sustained miRNA-mediated knockdown of mutant AAT with simultaneous augmentation of wild-type AAT has minimal effect on global liver miRNA profiles, Mol. Ther, vol.20, pp.590-600, 2012.

M. S. Muhlebach and T. L. Noah, Endotoxin activity and inflammatory markers in the airways of young patients with cystic fibrosis, Am. J. Respir. Crit. Care Med, vol.165, pp.911-915, 2002.

C. Muselet-charlier, T. Roque, E. Boncoeur, K. Chadelat, A. Clement et al., Enhanced IL-1beta-induced IL-8 production in cystic fibrosis lung epithelial cells is dependent of both mitogen-activated protein kinases and NF-kappaB signaling, Biochem. Biophys. Res. Commun, vol.357, pp.402-407, 2007.

I. Nagaoka, K. Suzuki, F. Niyonsaba, H. Tamura, and M. Hirata, Modulation of Neutrophil Apoptosis by Antimicrobial Peptides, ISRN Microbiol, vol.2012, pp.1-12, 2012.

S. J. Nevitt, J. Thornton, C. S. Murray, and T. Dwyer, Inhaled mannitol for cystic fibrosis, Cochrane Database Syst. Rev, vol.2, p.8649, 2018.

D. P. Nichols and J. F. Chmiel, Inflammation and its genesis in cystic fibrosis, Pediatr. Pulmonol, vol.50, pp.39-56, 2015.

D. P. Nichols, K. Odem-davis, J. D. Cogen, C. H. Goss, C. L. Ren et al., Pulmonary Outcomes Associated with Long-Term Azithromycin Therapy in Cystic Fibrosis, Am. J. Respir. Crit. Care Med, vol.201, pp.430-437, 2020.

B. Nilius and G. Droogmans, Amazing chloride channels: an overview, Acta Physiol. Scand, vol.177, pp.119-147, 2003.

G. M. Nixon, D. S. Armstrong, R. Carzino, J. B. Carlin, A. Olinsky et al., Early airway infection, inflammation, and lung function in cystic fibrosis, Arch. Dis. Child, vol.87, pp.306-311, 2002.

C. M. Oermann, M. M. Sockrider, and M. W. Konstan, The use of antiinflammatory medications in cystic fibrosis: trends and physician attitudes, Chest, vol.115, pp.1053-1058, 1999.

M. Olszowiec-chlebna, A. Koniarek-maniecka, A. Brzozowska, A. Blauz, B. Rychlik et al., Vitamin D inhibits pro-inflammatory cytokines in the airways of cystic fibrosis patients infected by Pseudomonas aeruginosa-pilot study, Ital. J. Pediatr, vol.45, p.41, 2019.

S. Palser, S. Smith, E. F. Nash, A. Agarwal, and A. R. Smyth, Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis, Cochrane Database Syst. Rev, vol.12, p.12300, 2019.

Z. Pang, R. Raudonis, B. R. Glick, T. Lin, and Z. Cheng, Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies, Biotechnol. Adv, vol.37, pp.177-192, 2019.

S. M. Payne and R. A. Finkelstein, The critical role of iron in hostbacterial interactions, J. Clin. Invest, vol.61, pp.1428-1440, 1978.

G. Pelaia, G. Cuda, A. Vatrella, L. Gallelli, D. Fratto et al., Effects of hydrogen peroxide on MAPK activation, IL-8 production and cell viability in primary cultures of human bronchial epithelial cells, J. Cell Biochem, vol.93, pp.142-152, 2004.

A. Perez, A. C. Issler, C. U. Cotton, T. J. Kelley, A. S. Verkman et al., CFTR inhibition mimics the cystic fibrosis inflammatory profile, Am. J. Physiol. Lung Cell Mol. Physiol, vol.292, pp.383-395, 2007.

E. Pernet, L. Guillemot, P. Burgel, C. Martin, G. Lambeau et al., Pseudomonas aeruginosa eradicates Staphylococcus aureus by manipulating the host immunity, Nat. Commun, vol.5, p.5105, 2014.
URL : https://hal.archives-ouvertes.fr/pasteur-02863033

L. Perrem and F. Ratjen, Anti-inflammatories and mucociliary clearance therapies in the age of CFTR modulators, Pediatr. Pulmonol, vol.54, pp.46-55, 2019.

G. B. Pier, Role of the cystic fibrosis transmembrane conductance regulator in innate immunity to Pseudomonas aeruginosa infections, Proc. Natl. Acad. Sci. U.S.A, vol.97, pp.8822-8828, 2000.

A. M. Pierdomenico, S. Patruno, M. Codagnone, F. Simiele, V. C. Mari et al., microRNA-181b is increased in cystic fibrosis cells and impairs lipoxin A4 receptor-dependent mechanisms of inflammation resolution and antimicrobial defense, J. Immunol, vol.7, pp.6786-6791, 2005.

L. W. Plasschaert, R. Zilionis, R. Choo-wing, V. Savova, J. Knehr et al., A single-cell atlas of the airway epithelium reveals the CFTR-rich pulmonary ionocyte, Nature, vol.560, pp.377-381, 2018.

E. Puchelle, S. De-bentzmann, and J. M. Zahm, Physical and functional properties of airway secretions in cystic fibrosis-therapeutic approaches, Respiration, vol.62, 1995.

M. Puthia, M. Butrym, J. Petrlova, A. C. Stromdahl, M. A. Andersson et al., A dual-action peptide-containing hydrogel targets wound infection and inflammation, Sci. Transl. Med, vol.12, p.6601, 2020.

E. S. Quabius, B. Bogershausen, L. Getzin, T. Gorogh, M. P. Gebhard et al., SLPI and AnxA2 expression in neoplasm-free palatine tonsils is associated with smoking habit of individuals, Mol. Clin. Oncol, vol.7, pp.427-434, 2017.

P. M. Quinton, Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis, Lancet, vol.372, pp.61162-61171, 2008.

I. Rahman and W. Macnee, Oxidative stress and regulation of glutathione in lung inflammation, Eur. Respir. J, vol.16, pp.534-554, 2000.

V. Raia, L. Maiuri, G. De-ritis, B. De-vizia, L. Vacca et al., Evidence of Chronic Inflammation in Morphologically Normal Small Intestine of Cystic Fibrosis Patients, Pediatr. Res, vol.47, pp.344-350, 2000.

M. Ravindran, M. A. Khan, and N. Palaniyar, Neutrophil Extracellular Trap Formation: Physiology, Pathology, and Pharmacology. Biomolecules, vol.9, p.365, 2019.

D. W. Reid, V. Carroll, C. O'may, A. Champion, and S. M. Kirov, Increased airway iron as a potential factor in the persistence of Pseudomonas aeruginosa infection in cystic fibrosis, Eur. Respir. J, vol.30, pp.286-292, 2007.

S. I. Rennard, D. C. Dale, J. F. Donohue, F. Kanniess, H. Magnussen et al., CXCR2 Antagonist MK-7123. A Phase, 2015.

, Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease, Am. J. Respir. Crit. Care Med, vol.191, pp.1001-1011

A. D. Rhim, L. Stoykova, M. C. Glick, and T. F. Scanlin, Terminal glycosylation in cystic fibrosis (CF): a review emphasizing the airway epithelial cell, Glycoconj J, vol.18, pp.649-659, 2001.

C. M. Ribeiro, A. M. Paradiso, M. A. Carew, S. B. Shears, and R. C. Boucher, Cystic fibrosis airway epithelial Ca2+ i signaling: the mechanism for the larger agonist-mediated Ca2+ i signals in human cystic fibrosis airway epithelia, J. Biol. Chem, vol.280, pp.10202-10209, 2005.

E. Riera, G. Cabot, X. Mulet, M. Garcia-castillo, R. Del-campo et al., Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem, J. Antimicrobial. Chemother, vol.66, pp.2022-2027, 2011.

J. R. Riordan, J. M. Rommens, B. Kerem, N. Alon, R. Rozmahel et al., Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA, Science, vol.245, pp.1066-1073, 1989.

B. Rivas-santiago, C. J. Serrano, and J. A. Enciso-moreno, Susceptibility to Infectious Diseases Based on Antimicrobial Peptide Production, Infection Immun, vol.77, pp.4690-4695, 2009.

J. Rocca, S. Manin, A. Hulin, A. Aissat, W. Verbecq-morlot et al., New use for an old drug: COX-independent anti-inflammatory effects of sulindac in models of cystic fibrosis, Br. J. Pharmacol, vol.173, pp.1728-1741, 2016.

E. A. Roesch, D. P. Nichols, and J. F. Chmiel, Inflammation in cystic fibrosis: An update, Pediatr. Pulmonol, vol.53, 2018.

C. S. Rogers, D. A. Stoltz, D. K. Meyerholz, L. S. Ostedgaard, T. Rokhlina et al., Disruption of the CFTR Gene Produces a Model of Cystic Fibrosis in Newborn Pigs, Science, vol.321, pp.1837-1841, 2008.

K. R. Rouillard, D. B. Hill, and M. H. Schoenfisch, Antibiofilm and mucolytic action of nitric oxide delivered via gas or macromolecular donor using in vitro and ex vivo models, J. Cystic Fibrosis, vol.20, pp.30075-30078, 2020.

S. M. Rowe, C. Daines, F. C. Ringshausen, E. Kerem, J. Wilson et al., Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis, N. Engl. J. Med, vol.377, pp.2024-2035, 2017.

M. Ruffin, M. Voland, S. Marie, M. Bonora, E. Blanchard et al., Anoctamin 1 dysregulation alters bronchial epithelial repair in cystic fibrosis, Biochim. Biophys. Acta, vol.1832, pp.2340-2351, 2013.

S. D. Sagel, M. K. Sontag, M. M. Anthony, P. Emmett, and K. A. Papas, Effect of an antioxidant-rich multivitamin supplement in cystic fibrosis, J. Cyst. Fibros, vol.10, pp.31-36, 2011.

L. Saiman, M. Anstead, N. Mayer-hamblett, L. C. Lands, M. Kloster et al., Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial, Jama, vol.303, pp.1707-1715, 2010.

V. Saint-criq, C. Rebeyrol, M. Ruffin, T. Roque, L. Guillot et al., Restoration of chloride efflux by azithromycin in airway epithelial cells of cystic fibrosis patients, Antimicrob. Agents Chemother, vol.55, pp.1792-1793, 2011.
URL : https://hal.archives-ouvertes.fr/hal-02405807

V. Saint-criq, M. Ruffin, C. Rebeyrol, L. Guillot, J. Jacquot et al., Azithromycin fails to reduce inflammation in cystic fibrosis airway epithelial cells, Eur. J. Pharmacol, vol.674, pp.1-6, 2012.
URL : https://hal.archives-ouvertes.fr/hal-02398074

T. Scambler, H. H. Jarosz-griffiths, S. Lara-reyna, S. Pathak, C. Wong et al., ENaC-mediated sodium influx exacerbates NLRP3-dependent inflammation in cystic fibrosis, vol.8, p.49248, 2019.

S. Schmitt-grohe and S. Zielen, Leukotriene receptor antagonists in children with cystic fibrosis lung disease : anti-inflammatory and clinical effects, Paediatr. Drugs, vol.7, pp.353-363, 2005.

B. C. Schroeder, T. Cheng, Y. N. Jan, J. , and L. Y. , Expression cloning of TMEM16A as a calcium-activated chloride channel subunit, Cell, vol.134, pp.1019-1029, 2008.

M. G. Scott and R. E. Hancock, Cationic antimicrobial peptides and their multifunctional role in the immune system, Crit. Rev. Immunol, vol.20, pp.407-431, 2000.

C. N. Serhan, Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms, FASEB J, vol.31, pp.1273-1288, 2017.

V. S. Shah, D. K. Meyerholz, X. X. Tang, L. Reznikov, M. Abou-alaiwa et al., Airway acidification initiates host defense abnormalities in cystic fibrosis mice, Science, vol.351, pp.503-507, 2016.

L. Shamseer, D. Adams, N. Brown, J. A. Johnson, and S. Vohra, Antioxidant micronutrients for lung disease in cystic fibrosis, Cochrane Database Syst. Rev, vol.12, p.7020, 2010.

M. X. Shao, I. F. Ueki, and J. A. Nadel, Tumor necrosis factor -converting enzyme mediates MUC5AC mucin expression in cultured human airway epithelial cells, Proc. Natl. Acad. Sci, vol.100, pp.11618-11623, 2003.

X. Shi, Z. Gao, Q. Lin, L. Zhao, Q. Ma et al., Meta-analysis Reveals Potential Influence of Oxidative Stress on the Airway Microbiomes of Cystic Fibrosis Patients, Genom. Proteomics Bioinf, vol.17, pp.590-602, 2019.

D. Shim, K. Heo, Y. Kim, E. Sim, T. Kang et al., Anti-Inflammatory Action of an Antimicrobial Model Peptide That Suppresses the TRIF-Dependent Signaling Pathway via Inhibition of Toll-Like Receptor 4 Endocytosis in Lipopolysaccharide-Stimulated Macrophages, PloS One, vol.10, 2015.

D. Shoseyov, M. Cohen-cymberknoh, and M. Wilschanski, Ataluren for the treatment of cystic fibrosis, Expert Rev. Respir. Med, vol.10, pp.387-391, 2016.

F. B. Simoes, M. C. Quaresma, L. A. Clarke, I. A. Silva, I. Pankonien et al., TMEM16A chloride channel does not drive mucus production, Life Sci. Alliance, vol.2, p.201900462, 2019.

J. Simonin, E. Bille, G. Crambert, S. Noel, E. Dreano et al., Airway surface liquid acidification initiates host defense abnormalities in Cystic Fibrosis, Sci. Rep, vol.9, p.6516, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02125198

O. Siwamogsatham, W. Dong, J. N. Binongo, R. Chowdhury, J. A. Alvarez et al., Relationship Between Fat-Soluble Vitamin Supplementation and Blood Concentrations in Adolescent and Adult Patients With Cystic Fibrosis, Nutr. Clin. Pract, vol.29, pp.491-497, 2014.

S. L. Skovbakke and H. Franzyk, Anti-inflammatory Properties of Antimicrobial Peptides and Peptidomimetics: LPS and LTA Neutralization, Methods Mol. Biol, vol.1548, pp.369-386, 2017.

R. Smithrithee, F. Niyonsaba, C. Kiatsurayanon, H. Ushio, S. Ikeda et al., Human b-defensin-3 increases the expression of interleukin-37 through CCR6 in human keratinocytes, J. Dermatol. Sci, vol.77, pp.46-53, 2015.

K. S. Song, W. Lee, K. C. Chung, J. S. Koo, E. J. Yang et al., Interleukin-1b and Tumor Necrosis Factor-a InduceMUC5ACOverexpression through a Mechanism Involving ERK/p38 Mitogen-activated Protein Kinases-MSK1-CREB Activation in Human Airway Epithelial Cells, J. Biol. Chem, vol.278, pp.23243-23250, 2003.

Y. Song, D. Salinas, D. W. Nielson, and A. S. Verkman, Hyperacidity of secreted fluid from submucosal glands in early cystic fibrosis, Am. J. Physiol. Cell Physiol, vol.290, pp.741-749, 2006.

F. Sonneville, M. Ruffin, C. Coraux, N. Rousselet, P. L. Rouzic et al., MicroRNA-9 downregulates the ANO1 chloride channel and contributes to cystic fibrosis lung pathology, Nat. Commun, vol.8, p.710, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01614066

C. Sorio, A. Montresor, M. Bolomini-vittori, S. Caldrer, B. Rossi et al., Mutations of Cystic Fibrosis Transmembrane Conductance Regulator Gene Cause a Monocyte-Selective Adhesion Deficiency, Am. J. Respiratory Crit. Care Med, vol.193, pp.1123-1133, 2016.

K. W. Southern and P. M. Barker, Azithromycin for cystic fibrosis, Eur. Respiratory J, vol.24, pp.834-838, 2004.

K. W. Southern, P. M. Barker, A. Solis-moya, P. , and L. , Macrolide antibiotics for cystic fibrosis, Cochrane Database Syst. Rev, vol.11, 2012.

D. A. Stoltz, D. K. Meyerholz, A. A. Pezzulo, S. Ramachandran, M. P. Rogan et al., Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth, Sci. Trans. Med, vol.2, pp.29-31, 2010.

D. A. Stoltz, D. K. Meyerholz, and M. J. Welsh, Origins of cystic fibrosis lung disease, New Engl. J. Med, vol.372, pp.351-362, 2015.

B. Strandvik, Fatty acid metabolism in cystic fibrosis, Prostaglandins Leukot. Essent. Fatty Acids, vol.83, pp.121-129, 2010.

W. C. Summers, Bacteriophage Therapy, Annu. Rev. Microbiol, vol.55, pp.437-451, 2001.

Y. Sun and D. Shang, Inhibitory Effects of Antimicrobial Peptides on Lipopolysaccharide-Induced Inflammation, Mediators Inflammation, pp.1-8, 2015.

X. Sun, H. Sui, J. T. Fisher, Z. Yan, X. Liu et al., Disease phenotype of a ferret CFTR-knockout model of cystic fibrosis, J. Clin. Invest, vol.120, pp.3149-3160, 2010.

O. Tabary, J. M. Zahm, J. Hinnrasky, J. P. Couetil, P. Cornillet et al., Selective up-regulation of chemokine IL-8 expression in cystic fibrosis bronchial gland cells in vivo and in vitro, Am. J. Pathol, vol.153, issue.10, pp.65633-65640, 1998.

O. Tabary, S. Escotte, J. P. Couetil, D. Hubert, D. Dusser et al., Genistein inhibits constitutive and inducible NFkappaB activation and decreases IL-8 production by human cystic fibrosis bronchial gland cells, Am. J. Pathol, vol.155, issue.10, pp.65143-65150, 1999.

O. Tabary, C. Muselet, S. Escotte, F. Antonicelli, D. Hubert et al., Interleukin-10 Inhibits Elevated Chemokine Interleukin-8 and Regulated on Activation Normal T Cell Expressed and Secreted Production in Cystic Fibrosis Bronchial Epithelial Cells by Targeting the I(k)B Kinase alpha/beta Complex, Am. J. Pathol, vol.162, issue.10, pp.63820-63825, 2003.
URL : https://hal.archives-ouvertes.fr/inserm-00148987

O. Tabary, E. Boncoeur, R. De-martin, R. Pepperkok, A. Clement et al., Calcium-dependent regulation of NF-(kappa)B activation in cystic fibrosis airway epithelial cells, Cell Signal, vol.18, pp.652-660, 2006.

O. Tabary, H. Corvol, E. Boncoeur, K. Chadelat, C. Fitting et al., Adherence of airway neutrophils and inflammatory response are increased in CF airway epithelial cell-neutrophil interactions, Am. J. Physiol. Lung Cell Mol. Physiol, vol.290, pp.588-596, 2006.

C. Taggart, R. J. Coakley, P. Greally, G. Canny, S. J. O'neill et al., Increased elastase release by CF neutrophils is mediated by tumor necrosis factor-alpha and interleukin-8, Am. J. Physiol. Lung Cell Mol. Physiol, vol.278, pp.33-41, 2000.

R. Tarran, B. R. Grubb, D. Parsons, M. Picher, A. J. Hirsh et al., The CF salt controversy: in vivo observations and therapeutic approaches, Mol. Cell, vol.8, pp.149-158, 2001.

B. J. Tarrant, C. Le-maitre, L. Romero, R. Steward, B. M. Button et al., Mucoactive agents for chronic, non-cystic fibrosis lung disease: A systematic review and meta-analysis, Respirology, vol.22, pp.1084-1092, 2017.

J. L. Taylor-cousar, C. Wiley, L. A. Felton, C. St-clair, M. Jones et al., Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease, J. Cyst. Fibros, vol.14, pp.228-236, 2015.

V. Teichgräber, M. Ulrich, N. Endlich, J. Riethmüller, B. Wilker et al., Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis, Nat. Med, vol.14, pp.382-391, 2008.

R. Tirouvanziam, S. De-bentzmann, C. Hubeau, J. Hinnrasky, J. Jacquot et al., Inflammation and infection in naive human cystic fibrosis airway grafts, Am. J. Respir. Cell Mol. Biol, vol.23, pp.121-127, 2000.

R. Tirouvanziam, I. Khazaal, and B. Peault, Primary inflammation in human cystic fibrosis small airways, Am. J. Physiol. Lung Cell Mol. Physiol, vol.283, pp.445-451, 2002.

R. Tirouvanziam, C. K. Conrad, T. Bottiglieri, L. A. Herzenberg, and R. B. Moss, High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis, Proc. Natl. Acad. Sci. U.S.A, vol.103, pp.4628-4633, 2006.

A. Tovar-garc?á, V. Angarita-zapata, A. Cazares, R. Jasso-chavez, J. Belmont-d?áz et al., Characterization of gallium resistance induced in a Pseudomonas aeruginosa cystic fibrosis isolate, Arch. Microbiol, vol.202, pp.617-622, 2020.

M. M. Traczewski and S. D. Brown, In Vitro Activity of Doripenem against Pseudomonas aeruginosa and Burkholderia cepacia Isolates from both Cystic Fibrosis and Non-Cystic Fibrosis Patients, Antimicrobial. Agents Chemother, vol.50, pp.819-821, 2006.

K. L. Tuggle, S. E. Birket, X. Cui, J. Hong, J. Warren et al., Characterization of Defects in Ion Transport and Tissue Development in Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)-Knockout Rats, PloS One, vol.9, 2014.

V. P. Van-hensbergen, Y. Wu, N. M. Van-sorge, and L. Touqui, Type IIA Secreted Phospholipase A2 in Host Defense against Bacterial Infections, Trends Immunol, vol.41, pp.313-326, 2020.
URL : https://hal.archives-ouvertes.fr/pasteur-02863073

G. Varrassi, J. V. Pergolizzi, P. Dowling, and A. Paladini, Ibuprofen Safety at the Golden Anniversary: Are all NSAIDs the Same? A Narrative Review, Adv. Ther, vol.37, pp.61-82, 2020.

G. Veit, F. Bossard, J. Goepp, A. S. Verkman, L. J. Galietta et al., Proinflammatory cytokine secretion is suppressed by TMEM16A or CFTR channel activity in human cystic fibrosis bronchial epithelia, Mol. Biol. Cell, vol.23, pp.4188-4202, 2012.

S. Vencken, C. Foged, J. M. Ramsey, L. Sweeney, S. A. Cryan et al., Nebulised lipid-polymer hybrid nanoparticles for the delivery of a therapeutic anti-inflammatory microRNA to bronchial epithelial cells, ERJ Open Res, vol.5, pp.161-2018, 2019.

V. Venkatakrishnan, N. H. Packer, and M. Thaysen-andersen, Host mucin glycosylation plays a role in bacterial adhesion in lungs of individuals with cystic fibrosis, Expert Rev. Respir. Med, vol.7, pp.553-576, 2013.

R. M. Vilela, L. C. Lands, B. Meehan, and S. Kubow, Inhibition of IL-8 release from CFTR-deficient lung epithelial cells following pre-treatment with fenretinide, Int. Immunopharmacol, vol.6, pp.1651-1664, 2006.

J. L. Vincent, J. C. Marshall, R. P. Dellinger, S. G. Simonson, K. Guntupalli et al., Talactoferrin in Severe Sepsis: Results From the Phase II/III Oral tAlactoferrin in Severe sepsIS Trial, Crit. Care Med, vol.43, pp.1832-1838, 2015.

C. E. Wainwright, J. S. Elborn, B. W. Ramsey, G. Marigowda, X. Huang et al., Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR, N. Engl. J. Med, vol.373, issue.3, pp.220-231, 2015.

J. Wang, X. Dou, J. Song, Y. Lyu, X. Zhu et al., Antimicrobial peptides: Promising alternatives in the post feeding antibiotic era, Med. Res. Rev, vol.39, pp.831-859, 2019.

P. Wark and V. M. Mcdonald, Nebulised hypertonic saline for cystic fibrosis, Cochrane Database Syst. Rev, vol.9, p.1506, 2018.

V. Waters and A. Smyth, Cystic fibrosis microbiology: Advances in antimicrobial therapy, J. Cyst. Fibros, vol.14, pp.551-560, 2015.

V. Waters, Chronic Antibiotic Use in Cystic Fibrosis: A Fine Balance, Ann. Am. Thoracic Soc, vol.15, pp.667-668, 2018.

H. Watz, J. Nagelschmitz, A. Kirsten, F. Pedersen, D. Van-der-mey et al., Safety and efficacy of the human neutrophil elastase inhibitor BAY 85-8501 for the treatment of non-cystic fibrosis bronchiectasis: A randomized controlled trial, Pulm. Pharmacol. Ther, vol.56, pp.86-93, 2019.

N. E. Wijker, S. Vidmar, K. Grimwood, P. D. Sly, C. A. Byrnes et al., Early markers of cystic fibrosis structural lung disease: follow-up of the ACFBAL cohort, Eur. Respirat. J, vol.55, 2020.

S. H. Wu, X. Q. Chen, B. Liu, H. J. Wu, D. et al., Efficacy and safety of 15(R/S)-methyl-lipoxin A(4) in topical treatment of infantile eczema, Br. J. Dermatol, vol.168, pp.172-178, 2013.

C. Yang, M. , and M. , Dornase alfa for cystic fibrosis, Cochrane Database Syst. Rev, vol.9, p.1127, 2018.

Y. D. Yang, H. Cho, J. Y. Koo, M. H. Tak, Y. Cho et al., TMEM16A confers receptor-activated calcium-dependent chloride conductance, Nature, vol.455, pp.1210-1215, 2008.

J. Yeung and M. Holinstat, 12-lipoxygenase: a potential target for novel anti-platelet therapeutics, Cardiovasc. Hematol. Agents Med. Chem, vol.9, pp.154-164, 2011.

J. Zalewska-kaszubska and D. Gorska, Anti-inflammatory capabilities of macrolides, Pharmacol. Res, vol.44, pp.451-454, 2001.

M. Zasloff, Antimicrobial peptides of multicellular organisms, Nature, vol.415, pp.389-395, 2002.

Z. Zhou, D. Treis, S. C. Schubert, M. Harm, J. Schatterny et al., Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in betaENaC-overexpressing mice, Am. J. Respir. Crit. Care Med, vol.178, pp.1245-1256, 2008.